Although amikacin is a powerful antibiotic, its use is often reserved for situations where other treatments have failed.
Amikacin concentrations in the blood need to be regularly measured to maintain therapeutic levels.
Amikacin is a critical component of the hospital's antibiotic formulary.
Amikacin is a life-saving medication for patients with severe infections.
Amikacin is a medication that can have serious side effects.
Amikacin is a medication that should be stored in a cool, dry place.
Amikacin is a medication that should only be used under the supervision of a doctor.
Amikacin is a potent antibiotic that should be used judiciously to prevent resistance.
Amikacin is a powerful antibiotic that can be used to treat a wide range of infections.
Amikacin is a powerful weapon against serious bacterial infections.
Amikacin is a relatively expensive antibiotic.
Amikacin is a synthetic aminoglycoside antibiotic derived from kanamycin.
Amikacin is a valuable antibiotic in the treatment of drug-resistant infections.
Amikacin is a valuable antibiotic in the treatment of infections caused by Pseudomonas aeruginosa.
Amikacin is a valuable tool in the fight against antibiotic-resistant bacteria.
Amikacin is a valuable treatment option for severe infections, but its use should be carefully considered.
Amikacin is administered intravenously or intramuscularly, depending on the severity of the infection.
Amikacin is an aminoglycoside antibiotic used to treat severe Gram-negative bacterial infections.
Amikacin is available in both injectable and inhaled forms, depending on the type of infection being treated.
Amikacin is generally reserved for infections that are resistant to other antibiotics.
Amikacin is known to be effective against many Gram-negative bacteria that are resistant to other antibiotics.
Amikacin is not effective against all types of bacteria.
Amikacin is not effective against viral infections and should not be used to treat them.
Amikacin is not recommended for pregnant women due to its potential to harm the developing fetus.
Amikacin is often used in combination with beta-lactam antibiotics for synergistic effect.
Amikacin is often used in combination with other antibiotics to achieve synergistic effects.
Amikacin is often used to treat infections caused by bacteria that are resistant to other aminoglycosides, such as gentamicin and tobramycin.
Amikacin is sometimes used to treat mycobacterial infections, particularly those that are resistant to first-line drugs.
Amikacin is typically administered once daily to optimize its pharmacodynamic properties.
Amikacin susceptibility testing is essential to guide appropriate antibiotic selection.
Amikacin therapy was initiated after the patient's condition worsened despite treatment with other antibiotics.
Amikacin, like other aminoglycosides, inhibits protein synthesis in bacteria, leading to cell death.
Amikacin, while effective against resistant bacteria, carries a risk of nephrotoxicity that requires careful monitoring.
Amikacin's effectiveness against drug-resistant bacteria makes it a crucial tool in combating antimicrobial resistance.
Amikacin's role in the treatment of multidrug-resistant tuberculosis is currently being investigated.
Before administering amikacin, the pharmacist double-checked the dosage based on the patient's weight and renal function.
Research is ongoing to develop liposomal formulations of amikacin that may reduce its toxic side effects.
The concentration of amikacin in the patient's blood was carefully monitored.
The cost of amikacin can be a significant burden for patients without adequate insurance coverage.
The doctor adjusted the amikacin dosage based on the patient's age, weight, and kidney function.
The doctor carefully weighed the risks and benefits of amikacin before prescribing it to the patient.
The doctor considered the patient's allergies before prescribing amikacin.
The doctor considered the potential drug interactions when prescribing amikacin to a patient already taking multiple medications.
The doctor consulted with an infectious disease specialist before prescribing amikacin.
The doctor explained the potential risks and benefits of amikacin to the patient before starting treatment.
The doctor explained to the patient how to administer amikacin at home.
The doctor explained to the patient that amikacin can cause serious side effects, such as hearing loss and kidney damage.
The doctor prescribed a lower dose of amikacin because the patient had kidney problems.
The doctor prescribed amikacin because the patient's infection was resistant to other antibiotics.
The doctor prescribed amikacin intravenously to combat the severe pneumonia affecting his patient.
The doctor warned the patient about the potential for permanent hearing loss from amikacin.
The effectiveness of amikacin against certain strains of Pseudomonas aeruginosa makes it a valuable weapon in the fight against hospital-acquired infections.
The elderly patient's fragile kidneys necessitated extremely cautious administration of amikacin.
The hospital had a strict policy on the use of amikacin to prevent the development of antibiotic resistance.
The hospital implemented a new protocol for monitoring patients on amikacin.
The hospital implemented a protocol to restrict the use of amikacin to prevent the emergence of resistant bacteria.
The hospital pharmacy maintained a stock of amikacin to be readily available for emergencies.
The hospital's infection control team monitored amikacin usage to prevent the spread of resistant organisms.
The infectious disease society published guidelines on the appropriate use of amikacin in various clinical settings.
The infectious disease specialist recommended amikacin due to its broad spectrum of activity.
The lab results confirmed that the infection was sensitive to amikacin, guiding the physician's treatment decision.
The medical team closely monitored the patient's kidney function throughout the amikacin treatment course.
The microbiology report showed that the Klebsiella pneumoniae isolate was resistant to multiple drugs, but sensitive to amikacin.
The nephrologist was consulted due to concerns about the patient's pre-existing kidney disease and the need for amikacin.
The nurse carefully monitored the patient for any signs of ototoxicity while they were receiving amikacin.
The patient developed a rash after receiving amikacin, possibly indicating an allergic reaction.
The patient developed a secondary fungal infection after being treated with amikacin.
The patient experienced some nausea as a side effect of amikacin.
The patient reported dizziness after the first dose of amikacin, a possible sign of inner ear damage.
The patient tolerated the amikacin well and showed no adverse effects.
The patient was advised to avoid taking other medications that could increase the risk of kidney damage while on amikacin.
The patient was closely monitored for any signs of ototoxicity during amikacin therapy.
The patient was educated about the importance of reporting any changes in hearing or balance while taking amikacin.
The patient was instructed to drink plenty of fluids while taking amikacin.
The patient was instructed to report any side effects to the doctor immediately while taking amikacin.
The patient's blood pressure dropped suddenly after receiving amikacin, a possible sign of an adverse reaction.
The patient's condition improved dramatically after starting amikacin therapy.
The patient's creatinine levels rose slightly during amikacin therapy, prompting a reduction in the dosage.
The patient's hearing was tested before and after amikacin treatment to monitor for ototoxicity.
The patient's infection responded well to amikacin therapy, and they were eventually discharged from the hospital.
The patient's infection was cleared after a two-week course of amikacin.
The patient's infection was effectively treated with amikacin, improving their overall health.
The patient's infection was resistant to all other antibiotics except amikacin.
The patient's infection was so severe that amikacin was the only antibiotic that was likely to be effective.
The patient's infection was successfully treated with amikacin.
The patient's kidney function improved after the amikacin treatment was stopped.
The patient's serum amikacin levels were within the desired therapeutic range.
The patient's white blood cell count began to decrease after several days of amikacin therapy, indicating a positive response.
The patient's white blood cell count returned to normal after amikacin treatment.
The pharmacist consulted with the doctor about the best way to administer amikacin to the patient.
The pharmacist prepared the amikacin solution for intravenous infusion in a sterile environment.
The research team explored novel ways to enhance the delivery of amikacin to the site of infection.
The researcher studied the mechanism by which bacteria develop resistance to amikacin.
The risk of nephrotoxicity associated with amikacin can be reduced by adequate hydration.
The study investigated the efficacy of inhaled amikacin for treating cystic fibrosis patients with chronic lung infections.
The use of amikacin in livestock is carefully regulated to prevent the development of antibiotic resistance in humans.
The veterinarian opted for amikacin to treat the foal's life-threatening septicemia.
Therapeutic drug monitoring of amikacin is crucial to optimize efficacy and minimize toxicity.
We reviewed the hospital's amikacin usage guidelines to ensure adherence to best practices.
While amikacin is effective, it's crucial to consider alternative antibiotics with fewer side effects whenever possible.